Multiple myeloma patients treated with BCMA-directed CAR T-cell therapy have high response rate

Bookmark and Share
Published: 7 Dec 2019
Views: 1154
Prof Deepu Madduri - Mount Sinai, New York, USA

Prof Deepu Madduri presents data from the CARTITUDE-1 study during a press conference at the ASH 2019 meeting.

The study evaluated the response rate of JNJ-4528, a CAR-T Cell Therapy directed against B-Cell maturation antigen (BCMA), in multiple myeloma patients.

Read more about the study here

Watch our interview with Prof Deepu Madduri here